Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
about
Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients.Monitoring of Busulphan Concentrations in Children Undergone Hematopoietic Stem Cell Transplantation: Unicentric Experience over 10 years.Clinical comparison of weight- and age-based strategy of dose administration in children receiving intravenous busulfan for hematopoietic stem cell transplantation.Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens.Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantationThe development of a myeloablative, reduced-toxicity, conditioning regimen for cord blood transplantation.Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation?Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome.Risk-adjusted monitoring of veno-occlusive disease following Bayesian individualization of busulfan dosage for bone marrow transplantation in paediatrics.Intravenous busulfan for allogeneic hematopoietic stem cell transplantation in infants: clinical and pharmacokinetic results.I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients.Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity.Influence of GST gene polymorphisms on busulfan pharmacokinetics in children.Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant.Continuous intravenous infusion of lorazepam as seizure prophylaxis in children treated with high-dose busulfan.Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review.Should busulfan therapeutic range be narrowed in pediatrics? Experience from a large cohort of hematopoietic stem cell transplant children.Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients.Increased risk of gastrointestinal acute GVHD following the addition of melphalan to busulfan/cyclophosphamide conditioning
P2860
Q36792760-09179296-A532-44C7-B426-EC6B1445BC58Q40085411-61454B26-9E76-4040-A8BC-43F9B9502FC1Q40170434-71D6265D-52EB-4C17-9854-48FB573392B4Q40667425-A446ECBA-FAA3-420E-A452-7A60C82F65AAQ41818881-0F7AE122-1227-4596-A6B8-2FB19DD20DA5Q41911583-7D1B1A4C-D72E-468E-878E-37FE2CCD28A6Q43248045-8C8FF385-E0B3-456A-9DA6-C4CAFED9DE9DQ43429437-671F40E8-6A66-4B13-B4A3-E6933CE15C3CQ43551135-ED5CA02B-B377-4374-A82D-D78B1843D9E3Q44586681-830CCF4F-7461-4024-8767-70DA2C64ADC1Q44830422-B4D50B6C-E654-4176-B04C-C8D072F2A32DQ45122639-FF45D9D1-6036-4FE1-A931-70D8F28302DDQ45936278-978EDB76-2512-44A1-AE49-D7F61C2A641EQ46138906-15185ABA-A913-4C78-BC03-8DB6CF015DBFQ46677131-1579BAB5-0536-4495-B98B-97B13C546FCEQ52552920-FEABE666-3C56-4E94-BF8F-0112B6B1E3F4Q53343875-ED7D1783-4457-44B5-9678-B82A202A7959Q53580759-D68651AE-1519-4EAF-B5A5-364B9C95A4DBQ58788918-4AFA107A-24F6-4262-A99B-E60FFAF1002B
P2860
Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation for advanced hematologic malignancies.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Individualizing high-dose oral ...... nced hematologic malignancies.
@en
Individualizing high-dose oral ...... nced hematologic malignancies.
@nl
type
label
Individualizing high-dose oral ...... nced hematologic malignancies.
@en
Individualizing high-dose oral ...... nced hematologic malignancies.
@nl
prefLabel
Individualizing high-dose oral ...... nced hematologic malignancies.
@en
Individualizing high-dose oral ...... nced hematologic malignancies.
@nl
P2093
P356
P1476
Individualizing high-dose oral ...... nced hematologic malignancies.
@en
P2093
Choroszy M
Danielson M
Petropoulos D
Przepiorka D
Sprigg-Saenz HA
P2888
P304
P356
10.1038/SJ.BMT.1702561
P407
P577
2000-09-01T00:00:00Z
P5875
P6179
1043348096